{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:33:44Z","timestamp":1790472824697,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hexal AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, peripheral and\/or axial spondyloarthritis, Crohn\u2019s disease, and ulcerative colitis, are characterized by molecular and cellular changes in the immune system. Due to the systemic nature of these diseases, organs such as the liver or cardiovascular system are often affected by the inflammatory process. Tumor necrosis factor-\u03b1 inhibitor therapy reduces the activation of pro-inflammatory signaling cascades, mitigates the chronic inflammatory process by restoring cellular balance, and alleviates clinical consequences, such as pain and tissue damage.<\/jats:p>","DOI":"10.3390\/jcm12155039","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:00:15Z","timestamp":1690797615000},"page":"5039","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Reversing the Inflammatory Process\u201425 Years of Tumor Necrosis Factor-\u03b1 Inhibitors"],"prefix":"10.3390","volume":"12","author":[{"given":"Katharina N.","family":"Muth","sequence":"first","affiliation":[{"name":"Medical Affairs, Hexal AG, 83607 Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-2029","authenticated-orcid":false,"given":"Juergen","family":"Rech","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian O.","family":"Losch","sequence":"additional","affiliation":[{"name":"Medical Affairs, Hexal AG, 83607 Holzkirchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-7168","authenticated-orcid":false,"given":"Andr\u00e9","family":"Hoerning","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"},{"name":"Clinic for Children and Adolescent Medicine, Friedrich-Alexander-University Erlangen-N\u00fcrnberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"key":"ref_1","first-page":"2155","article-title":"An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites","volume":"28","author":"McGonagle","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8549-4_5","article-title":"Markers of inflammation","volume":"1803","author":"Germolec","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fimmu.2018.00089","article-title":"The role of cytochromes P450 in infection","volume":"9","author":"Stavropoulou","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41584-021-00652-9","article-title":"Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases","volume":"17","author":"Szekanecz","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.autrev.2018.10.005","article-title":"Innate immune-responses and their role in driving autoimmunity","volume":"18","author":"Toubi","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2613.2001.iep192.x","article-title":"The functions of cytokines and their uses in toxicology","volume":"82","author":"Foster","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/imr.12671","article-title":"Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology","volume":"285","author":"Cicchese","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2013.03.002","article-title":"Development and maintenance of regulatory T cells","volume":"38","author":"Ohkura","year":"2013","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2017.12.006","article-title":"Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis","volume":"87","author":"Tas","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pesce, B., Ribeiro, C.H., Larrondo, M., Ramos, V., Soto, L., Catal\u00e1n, D., and Aguill\u00f3n, J.C. (2022). TNF-\u03b1 affects signature cytokines of Th1 and Th17 T cell subsets through differential actions on TNFR1 and TNFR2. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169306"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","article-title":"Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors","volume":"44","author":"Aeberli","year":"2005","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e13116","DOI":"10.1111\/sji.13116","article-title":"Resolution of Th\/Tc17-driven inflammation during anti-TNF\u03b1 treatment of rheumatoid arthritis reveals a unique immune biomarker profiling pattern","volume":"95","author":"Helgason","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3748\/wjg.14.4280","article-title":"Role of cytokines in inflammatory bowel disease","volume":"14","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"de Jong, L.M., Jiskoot, W., Swen, J.J., and Manson, M.L. (2020). Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: Lessons from experimental models and a potential role for pharmacogenetics. Genes, 11.","DOI":"10.3390\/genes11121509"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"733935","DOI":"10.3389\/fphar.2021.733935","article-title":"Influence of inflammation on cytochromes P450 activity in adults: A systematic review of the literature","volume":"12","author":"Lenoir","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment","volume":"215","author":"Chhun","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1124\/dmd.118.082065","article-title":"Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis","volume":"46","author":"Wollmann","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00281-022-00910-2","article-title":"TNF in the liver: Targeting a central player in inflammation","volume":"44","author":"Tiegs","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4038619","DOI":"10.1155\/2019\/4038619","article-title":"Anti-TNF-\u03b1 monoclonal antibody therapy improves anemia through downregulating hepatocyte hepcidin expression in inflammatory bowel disease","volume":"2019","author":"Shu","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102956","DOI":"10.1016\/j.ebiom.2020.102956","article-title":"Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study","volume":"59","author":"Yuan","year":"2020","journal-title":"EBiomedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/ibd\/izaa258","article-title":"Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease","volume":"27","author":"Sinh","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cyto.2016.09.001","article-title":"TNF\u03b1 in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases","volume":"101","author":"Bystrom","year":"2018","journal-title":"Cytokine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1038\/s41598-018-26097-x","article-title":"Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases","volume":"8","author":"Sauzullo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fphar.2020.00939","article-title":"Probable drug interaction between etanercept and cyclosporine resulting in clinically unexpected low trough concentrations: First case report","volume":"11","author":"Wen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ibd\/izaa054","article-title":"Distribution and cytokine profile of peripheral B cell subsets is perturbed in pediatric IBD and partially restored during a successful IFX therapy","volume":"27","author":"Schnell","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.intimp.2017.11.016","article-title":"Anti-tumour necrosis factor-\u03b1 antibodies and B cell homeostasis in human inflammatory bowel diseases","volume":"54","author":"Defendenti","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1097\/MIB.0000000000000554","article-title":"Anti-tumor necrosis factor therapy restores peripheral blood B-cell subsets and CD40 expression in inflammatory bowel diseases","volume":"21","author":"Li","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00054725-200411000-00015","article-title":"Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn\u2019s disease","volume":"10","author":"Ringheanu","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/cyto.2001.0919","article-title":"Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn\u2019s disease","volume":"15","author":"Agnholt","year":"2001","journal-title":"Cytokine"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Holleran, G., Lopetuso, L., Petito, V., Graziani, C., Ianiro, G., McNamara, D., Gasbarrini, A., and Scaldaferri, F. (2017). The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102020"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/JIR.S292513","article-title":"In vitro phenotype induction of circulating monocytes: CD16 and CD163 analysis","volume":"14","author":"Karsulovic","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1084\/jem.20061531","article-title":"Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta","volume":"204","author":"Nadkarni","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/art.34565","article-title":"Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy","volume":"64","author":"McGovern","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2017.05.012","article-title":"Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy","volume":"184","author":"Pozsgay","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_42","first-page":"173ra123","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Bosma","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10067-013-2359-3","article-title":"Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis","volume":"33","author":"Ma","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-017-1244-x","article-title":"Th17 and CD24(hi)CD27(+) regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis","volume":"19","author":"Salomon","year":"2017","journal-title":"Arthritis. Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/annrheumdis-2020-218304","article-title":"Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo","volume":"80","author":"Menegatti","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: An open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MPG.0000000000003643","article-title":"Adalimumab therapy in pediatric Crohn disease: A 2-year follow-up comparing \u201ctop-down\u201d and \u201cstep-up\u201d strategies","volume":"76","author":"Payen","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jongsma, M.M.E., Costes, L.M.M., Tindemans, I., Cozijnsen, M.A., Raatgreep, R.H.C., van Pieterson, M., Li, Y., Escher, J.C., de Ridder, L., and Samsom, J.N. (2023). Serum immune profiling in pediatric Crohn\u2019s disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments. J. Crohns Colitis, jjad049.","DOI":"10.1093\/ecco-jcc\/jjad049"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"903677","DOI":"10.3389\/fped.2022.903677","article-title":"Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease\u2014Data from the multicenter CEDATA-GPGE registry study","volume":"10","author":"Schnell","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_50","first-page":"421","article-title":"Early immune suppression in children and adolescents with Crohn\u2019s disease\u2014Data from the CEDATA GPGE registry","volume":"118","author":"Zimmer","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-\u03b1 vs an immunomodulator in children with Crohn\u2019s disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"814429","DOI":"10.3389\/fimmu.2022.814429","article-title":"The risk of adverse effects of TNF-\u03b1 inhibitors in patients with rheumatoid arthritis: A network meta-analysis","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/rheumatology\/key209","article-title":"The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: Report from a National Consensus Conference","volume":"57","author":"Conti","year":"2018","journal-title":"Rheumatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_56","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (2023, May 15). Januskinase-Inhibitoren: Behandlung von Entz\u00fcndungskrankheiten. Available online: https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/g-l\/januskinase.html;jsessionid=BD9413EADD5BFB59861897542E2169D0.internet281?nn=471274."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/00365521.2017.1416161","article-title":"Re-evaluating osteoporosis and fracture risk in Crohn\u2019s disease patients in the era of TNF-alpha inhibitors","volume":"53","author":"Hakimiana","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00296-017-3702-9","article-title":"Identification and management of comorbidity in psoriatic arthritis: Evidence- and expert-based recommendations from a multidisciplinary panel from Spain","volume":"37","author":"Carmona","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00296-014-3196-7","article-title":"Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis","volume":"35","author":"Loza","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cla\u00dfen, M., and Hoerning, A. (2023). Current role of monoclonal antibody therapy in pediatric IBD: A special focus on therapeutic drug monitoring and treat-to-target strategies. Children, 10.","DOI":"10.3390\/children10040634"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Mangano, K., Petralia, M.C., Nicoletti, F., and Fagone, P. (2023). Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041630"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/1389201019666171226151852","article-title":"Biologics in Inflammatory and Immunomediated Arthritis","volume":"18","author":"Luchetti","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","article-title":"Long-term safety and effectiveness of etanercept in JIA: An 18-year experience from the BiKeR registry","volume":"22","author":"Armaroli","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"416892","DOI":"10.1155\/2014\/416892","article-title":"Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen Registry","volume":"2014","author":"Filippini","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10067-021-05893-3","article-title":"Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: A postmarketing, noninterventional, observational study","volume":"41","author":"Karadag","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","article-title":"Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research","volume":"22","author":"Gladman","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"otab060","DOI":"10.1093\/crocol\/otab060","article-title":"Early start of infliximab in Crohn\u2019s Disease increases rates of endoscopic remission and decreases stenosis formation: Experiences from a single center cohort","volume":"3","author":"Schnitzler","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., Lees, C., Louis, E., Luk\u00e1\u0161, M., and Reinisch, W. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02347-1"},{"key":"ref_69","first-page":"1232","article-title":"Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis","volume":"32","author":"Genovese","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Marquez-Megias, S., Nalda-Molina, R., Sanz-Valero, J., M\u00e1s-Serrano, P., Diaz-Gonzalez, M., Candela-Boix, M.R., and Ramon-Lopez, A. (2022). Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051009"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Martelli, L., Olivera, P., Roblin, X., Attar, A., and Peyrin-Biroulet, L. (2017). Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: A systematic review. J. Gastroenterol.","DOI":"10.1007\/s00535-016-1266-1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31,846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"178","DOI":"10.21037\/atm-23-195","article-title":"Efficacy and safety of IL inhibitors, TNF-\u03b1 inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: A systematic review and Bayesian network meta-analysis","volume":"11","author":"Tian","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Baraliakos, X., Ostergaard, M., Poddubnyy, D., van der Heijde, D., Deodhar, A., Machado, P.M., Navarro-Comp\u00e1n, V., Hermann, K.G., Kishimoto, M., and Lee, E.Y. (2022, January 10\u201314). Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: A randomized phase IIIb study. Proceedings of the American College of Rheumatology Convergence 2022, Philadelphia, PA, USA.","DOI":"10.1136\/annrheumdis-2023-eular.301"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.14309\/ajg.0000000000001795","article-title":"Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn\u2019s Disease","volume":"117","author":"Narula","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.neuroscience.2008.08.067","article-title":"Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro","volume":"157","author":"Sommer","year":"2008","journal-title":"Neuroscience"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1011774108","article-title":"Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system","volume":"108","author":"Hess","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/j.gastro.2015.05.063","article-title":"Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn\u2019s Disease","volume":"149","author":"Hess","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/ard.2009.107912","article-title":"Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: A clinical, proof-of-concept study","volume":"69","author":"Cavanagh","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"621247","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41575-022-00663-1","article-title":"Gut immune cell trafficking: Inter-organ communication and immune-mediated inflammation","volume":"20","author":"Zundler","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management","volume":"4","author":"Li","year":"2019","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14218\/JCTH.2021.00243","article-title":"Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies","volume":"10","author":"Hernandez","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bouhuys, M., Lexmond, W.S., and van Rheenen, P.F. (2022). De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051034"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S2665-9913(21)00220-4","article-title":"Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"3","author":"Taskilar","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Stephan, M., Tascilar, K., Yalcin-Mutlu, M., Hagen, M., Haschka, J., Reiser, M., Hartmann, F., Kleyer, A., Hueber, A.J., and Manger, B. (2023). Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial. J. Clin. Med., 12.","DOI":"10.20944\/preprints202304.1014.v1"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.14309\/ajg.0000000000000783","article-title":"Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review","volume":"115","author":"Little","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/ecco-jcc\/jjaa087","article-title":"Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"14","author":"Zhang","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13063-019-4000-5","article-title":"Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: Design of a pragmatic open-label, randomised, non-inferiority trial","volume":"21","author":"Michielsens","year":"2020","journal-title":"Trials"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 years after infliximab withdrawal for patients with Crohn\u2019s Disease in sustained remission","volume":"16","author":"Reenaers","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11894-018-0643-8","article-title":"De-escalation of Therapy in Inflammatory Bowel Disease","volume":"20","author":"Gomes","year":"2018","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Louis, E., Resche-Rigon, M., Laharie, D., Satsangi, J., Ding, N., Siegmund, B., D\u2019Haens, G., Picon, L., Bossuyt, P., and Vuitton, L. (2023). Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): A multicentre, open-label, randomised controlled trial. Lancet Gastroenterol. Hepatol., 215\u2013227.","DOI":"10.1016\/S2468-1253(22)00385-5"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e000900","DOI":"10.1136\/rmdopen-2019-000900","article-title":"Era of biosimilars in rheumatology: Reshaping the healthcare environment","volume":"5","author":"Smolen","year":"2019","journal-title":"RMD Open"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14712598.2020.1812575","article-title":"Real-world observational study of biosimilars in inflammatory arthritis treatment: A systematic literature review","volume":"21","author":"Kim","year":"2020","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:23:15Z","timestamp":1760127795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/15\/5039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":95,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["jcm12155039"],"URL":"https:\/\/doi.org\/10.3390\/jcm12155039","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]}}}